Graydon Harker

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 551 citations

Breast Oncology, Health Sciences, Medicine +9

Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer

Charles S. Fuchs, M. R. Moore, Graydon Harker et al. · Journal of Clinical Oncology · 2003 · 298 citations

Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer

Ghassan K. Abou‐Alfa, Richard Létourneau, Graydon Harker et al. · Journal of Clinical Oncology · 2006 · 277 citations · Full text

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.

John D. Hainsworth, W. Henwood Harvey, Kelly Pendergrass et al. · Journal of Clinical Oncology · 1991 · 154 citations

Drug Safety, Medicine, Psychotropic Medication +14

A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer

B. Mirtsching, Thomas M. Cosgriff, Graydon Harker et al. · Clinical Breast Cancer · 2011 · 67 citations

Nanomedicine, Metastatic Breast Cancer, Oncology +10